Oman MOH Registered Devices Teardown & Class C/D Transition
A data teardown of the 502 medicated devices on the Oman MOH register, detailing the dermatology and ophthalmology category skews, local agent concentration, and the new Class C/D mandate.
Oman MOH Registered Medical Devices Teardown: 502 Medicated Devices, Dermatology-and-Ophthalmology Manufacturer Mix, Local-Agent Channel Concentration, and the July 2025 Mandatory Class C/D Registration Transition
Oman occupies a unique position in the Gulf Cooperation Council (GCC). While smaller than neighboring Saudi Arabia and the United Arab Emirates, it represents a stable, high-income healthcare market with a strong government commitment to expanding clinical infrastructure. As international medical device and in vitro diagnostic (IVD) manufacturers map out their Middle Eastern expansion strategies, Oman is undergoing a fundamental regulatory transformation that makes it one of the most freshness-sensitive markets in the region.
Historically, Oman’s Ministry of Health (MOH) regulated only a narrow band of medical products directly. However, the publication of Circular No. 161/2025 in July 2025 initiated a transition from a voluntary notification and import-permit clearance model to a strict, mandatory risk-based registration system. With the July 1, 2026 mandatory deadline fast approaching, manufacturers must move quickly to secure formal product approvals or risk losing market access.
To help regulatory affairs, market access, and distributor-management teams navigate this transition, this article provides a detailed quantitative analysis of the Omani register. We analyze the Oman MOH Drug Safety Center registered medicated medical devices (502 records) and the approved medical-device establishments list (81 entities). This dataset provides a clear window into the existing commercial channel, manufacturer concentrations, and Omani agent dominance.
Skip to Your Scenario
To help you navigate this comprehensive guide, select the scenario that best matches your current strategic objective:
- How many medical devices are on the MOH register and what categories dominate? — Scope definition and product category analysis.
- Which manufacturers dominate Oman's register (the dermatology/ophthalmology/aesthetic skew)? — Competitive landscape profiling.
- Which Omani local agents and approved establishments hold the channel (concentration)? — Partner analysis and channel lock-in risks.
- What changed with Circular 161/2025 and the mandatory Class C/D registration (July 2025 - July 2026)? — Analyzing the mandatory registration timeline.
- What are the fees, timeline, and reference-market recognition for Oman MOH registration? — Regulatory planning and budget metrics.
- Side-by-Side Regulatory Comparison Across the GCC — Oman vs. Saudi Arabia, UAE, Qatar, and Bahrain.
- Detailed Step-by-Step Oman MOH Registration Workflow — Dossier compilation and approval milestones.
- Strategic Local-Agent Selection and Channel-Lock-In Avoidance for Oman — Commercial execution guidelines.
How many medical devices are on the MOH register and what categories dominate?
The first and most critical step in analyzing Oman’s data is understanding its scope limitation. The historical register maintained by the MOH Drug Safety Center contains 502 registered records (corresponding to 500 unique registration numbers, as two records represent minor packaging variations).
This register does not represent every medical device used in Omani hospitals. Instead, it is a dedicated registry for "Medicated Medical Devices" — a specific regulatory classification for medical devices that incorporate a pharmaceutical active ingredient or a drug substance, or possess clinical properties that border on pharmaceutical products. This includes products like medicated wound dressings, ophthalmic preparations, dermal fillers, specialized saline/viscoelastic solutions, and clinical skin treatments.
A breakdown of the registered products by their official main_group category reveals a massive skew:
| Product Main Group (Official Category) | Number of Records | Percentage of Registry | Key Examples in Dataset |
|---|---|---|---|
| Dermatology / Skin Management | 197 | 39.2% | Dermal fillers, barrier creams, clinical skin cleansers, antiseptic washes |
| Ophthalmology / Eye Preparations | 94 | 18.7% | Viscoelastic solutions, clinical eye drops, contact lens solutions |
| ENT (Ear, Nose, & Oropharynx) | 72 | 14.3% | Saline nasal sprays, nasal decongestant lines, throat solutions |
| Wound Management & Elastic Hosiery | 26 | 5.2% | Medicated wound dressings, compression wraps, surgical tape |
| Rheumatic Diseases & Gout | 26 | 5.2% | Intra-articular sodium hyaluronate injections |
| Other Specialties (Antiseptics, Gynecology, etc.) | 87 | 17.3% | Vaginal douches, anti-lice treatments, anal lubricants |
| Total | 502 | 100.0% | MOH Medicated Device Registry |
The Clinical Implication of the Category Skew
Dermatological and skin management products represent 39.2% of the register (197 records), followed closely by ophthalmic preparations at 18.7% (94 records). Together, these two clinical categories account for almost 60% of all registered medicated devices.
This tells us that the Omani MOH has historically focused its pre-market registration scrutiny on products that represent boundary cases between devices and drugs. Hyaluronic acid dermal fillers, intra-articular joint injections, and ophthalmic lubricants are heavily regulated because their mechanisms of action can overlap with pharmacological processes. For companies manufacturing these border-case technologies, Oman’s regulatory barrier has always been high.
Which manufacturers dominate Oman's register (the dermatology/ophthalmology/aesthetic skew)?
The manufacturer list in Oman's register is European-heavy, reflecting a high-end clinical supply chain for dermatological and ophthalmic care. Our analysis identifies 197 distinct manufacturers holding approvals.
The top manufacturers by record count are:
- Mundipharma MEA (~13 records): Dominates the clinical skin cleanser, throat, and antiseptic wash categories.
- D.O.R.C. (Dutch Ophthalmic Research Center) (~13 records): Leads the ophthalmic segment with surgical viscoelastics and diagnostic dyes.
- Artsana (~12 records): Focused on clinical wound dressings and basic patient-care consumables.
- TEOXANE (~12 records): A leading Swiss developer of hyaluronic acid dermal fillers.
- Croma-Pharma (~11 records): An Austrian pharmaceutical and device manufacturer specializing in aesthetics and ophthalmology.
- Allergan (~10 records): The global giant behind Botox and Juvederm dermal filler lines.
Geographic Origin of Manufacturers
Analyzing the country-of-origin for these products is challenging because the raw dataset contains a high proportion of missing or unparsed origin fields (411 out of 502 records). However, for the 91 records where the manufacturer's country can be parsed, European origins dominate:
Parsed Country of Origin (Subset of 91 Records):
Italy: ███████████████ 15
Switzerland: ██████████████ 14
Germany: █████████████ 13
France: ███████████ 11
Ireland: ███████ 7
India: ██████ 6
UAE / Saudi: ██████████ 10 (combined)
This distribution highlights the heavy reliance on premium European clinical supplies. Swiss and French manufacturers dominate the aesthetic dermal filler segment (TEOXANE, Allergan), while Italian and German manufacturers lead the wound care and ophthalmic supply lines (Artsana, D.O.R.C.). The low representation of Asian manufacturers (except for a few Indian consumable brands) suggests a significant untapped opportunity for high-quality, cost-competitive manufacturers who can successfully navigate the new registration hurdles.
Which Omani local agents and approved establishments hold the channel (concentration)?
In the GCC, the commercial channel is highly regulated, and local partner selection can determine the success or failure of a market entry. Oman requires every foreign manufacturer to operate through a licensed local representative who holds a valid license from the MOH.
Our analysis of the local agents holding the 502 medicated device registrations reveals an extreme channel concentration. Out of approximately 90 distinct local agents, a small handful controls the vast majority of registrations:
Oman Local Agent Registration Shares (502 Total):
Muscat Pharmacy & Stores: ██████████████████████████████ 78 (15.5%)
Orbit Medical Supplies: █████████████ 33 (6.6%)
Dawaku'm: █████████ 23 (4.6%)
Scientific Pharmacy: ███████ 19 (3.8%)
Arabian Medical Enterprises:██████ 16 (3.2%)
Others (approx. 85 agents):█████████████████████████████████████████ 333 (66.3%)
The Dominance of Muscat Pharmacy & Stores
Muscat Pharmacy & Stores L.L.C. holds 78 registrations (listed under two minor name-case variations in the registry, 45 and 33). This represents 15.5% of the entire register, making it the single most powerful regulatory and commercial gateway for medicated devices in the Sultanate.
Muscat Pharmacy acts as the local authorized representative for major global firms (including Mundipharma and Allergan), controlling their legal import pathways. The next tier of distributors — Orbit Medical Supplies (33), Dawaku'm (23), and Scientific Pharmacy (19) — also holds substantial portfolios.
Strategic Risks: Channel Lock-In and Sibling Comparisons
This concentration creates a significant channel lock-in risk for foreign manufacturers:
- Once a local agent registers your device, the registration is linked to their commercial establishment.
- If the distributor underperforms, transferring the registration to a new agent requires a formal "No Objection Certificate" (NOC) from the existing agent, which can be difficult and expensive to secure.
- The Sibling Pattern: This commercial dynamic mirrors our findings in other GCC registry teardowns. For instance, in the Saudi SFDA authorized representative concentration and expiry-risk analysis and the Bahrain NHRA authorized representative concentration and GCC channel lock-in analysis, a few mega-distributors (like Farouk, Muscat, or regional equivalents) hold the channel. To mitigate this risk, sophisticated manufacturers are increasingly using third-party regulatory hold models or structuring multi-agent contracts that separate regulatory representation from physical distribution.
What changed with Circular 161/2025 and the mandatory Class C/D registration (July 2025 - July 2026)?
Prior to July 2025, non-medicated medical devices (ranging from scalpels to MRI machines) did not require formal product-specific registration. They were imported using a simplified notification process, where the importer submitted the manufacturer’s CE Mark or FDA clearance to secure a local import permit.
This system was completely overhauled by Circular No. 161/2025, which established a mandatory, risk-based registration framework.
The Phased Implementation Timeline
To prevent market supply disruptions, the Omani MOH structured the transition in phases:
- July 2025 (Launch Phase): MOH officially published Circular 161/2025, defining the new Class A-D risk classification system, which is aligned with the GHTF principles.
- August 11, 2025 (Digital Portal Launch): The online e-portal for medical device registration went live. The MOH opened the submission fields for Class C (moderate-high risk) and Class D (high-risk) medical devices.
- November 2025 (Manufacturer Pre-Qualification): The MOH Drug Safety Center published Guideline GD-22 ("Guideline on Requirements of Medical Device Manufacturer Registration in the Sultanate of Oman"). This document established that foreign manufacturing facilities must be registered and pre-qualified before any product dossiers can be submitted.
- July 1, 2026 (The Hard Deadline): Full compliance becomes mandatory. After this date, no Class C or Class D devices can be imported into Oman without a formal MOH Registration Certificate. Class A and B devices must follow the new enlistment procedures.
What are the fees, timeline, and reference-market recognition for Oman MOH registration?
For commercial planning, the new Omani MOH registration system features the following parameters:
- Official Timeline: The MOH commits to a processing window of 60 working days from the receipt of a complete application. However, if the MOH issues deficiency questions, the clock stops, and the actual timeline can stretch to 4 to 6 months.
- Government Fees: The fee schedule is structured to reflect product risk:
- Class A & Class B (Low & Low-Moderate Risk): OMR 100 per registration.
- Class C & Class D (Moderate-High & High-Risk): OMR 200 per registration.
- Note on local costs: These represent government fees only. They do not include the fees charged by local Omani authorized representatives (which can range from OMR 500 to OMR 2,500/year to hold the registration) or legal translation and document legalization costs.
- Reference-Market Recognition: To streamline the 60-working-day review, Oman heavily utilizes reference-market approvals. Providing evidence of active approval in one of the following markets is essential:
- Saudi Arabia (SFDA MDMA approval) — highly preferred due to GCC alignment
- United States (FDA 510k/PMA clearance)
- European Union (MDR/IVDR CE Mark)
- Canada (Health Canada Device License)
- Australia (TGA conformity certificate)
- Japan (PMDA approval)
Side-by-Side Regulatory Comparison Across the GCC
For international manufacturers coordinating a Middle Eastern rollout, understanding the differences between GCC jurisdictions is vital. While the GCC aims for harmonization, significant administrative differences remain:
| Regulatory Parameter | Oman (MOH) | Saudi Arabia (SFDA) | UAE (MOHAP) | Bahrain (NHRA) | Qatar (MOPH) |
|---|---|---|---|---|---|
| Governing Body | Drug Safety Center | Medical Devices Sector | Public Health Section | Medical Devices Dept | Pharmacy & MD Dept |
| System Maturity | Mid-Transition | Highly Mature | Mature | Transitional | Early Stage |
| Portal Name | MOH E-Portal | GHAD / Unified Portal | MoHAP MD System | NHRA E-Services | MOPH Import Portal |
| Government Fee | OMR 100 - 200 | SAR 9,000 - 19,000 | AED 1,000 - 5,000 | BHD 100 - 500 | QAR 500 - 2,000 |
| Review Timeline | 60 Working Days | 35 - 90 Days | 45 - 90 Days | 60 - 90 Days | 60 - 120 Days |
| Validity Period | 5 Years | 3 Years | 5 Years | 3 Years | 3 Years |
| Local Rep (AR) | Mandatory (Omani) | Mandatory (Saudi) | Mandatory (Emirati) | Mandatory (Bahraini) | Mandatory (Qatari) |
| Reference Markets | Yes (FDA, CE, etc.) | Yes (FDA, CE, TGA) | Yes (FDA, CE, PMDA) | Yes (FDA, CE, SFDA) | Yes (FDA, CE, SFDA) |
Analyzing the GCC Regulatory Map
Oman occupies a middle-ground in the GCC. Its fees (OMR 100 to 200, equivalent to approximately $260 to $520 USD) are significantly lower than Saudi Arabia's steep SFDA fee schedule, which can easily reach several thousand dollars per device family. However, the requirement for Omani embassy legalization of Free Sale Certificates (FSCs) can add substantial upfront costs and delay timelines by several weeks.
Crucially, like Bahrain and Qatar, Oman accepts Saudi SFDA approvals as a major positive review factor. If you have already secured a Saudi MDMA certificate, your Omani representative can utilize this as the primary reference-market evidence on the portal, often clearing technical review with fewer deficiency letters.
Detailed Step-by-Step Oman MOH Registration Workflow
Navigating the new Omani MOH regulatory pathway requires a structured administrative sequence. Below is the operational workflow for manufacturers entering the market:
+---------------------------------------------------------------------------------+
| Oman MOH Registration Pipeline |
+---------------------------------------------------------------------------------+
|
[Step 1: Local Agent Appointment] -> Establish relationship + legal contract
|
[Step 2: GD-22 Manufacturer Reg] -> Pre-qualify the factory site (MOH approval)
|
[Step 3: Dossier Compilation] -> CSDT structure + reference approvals
|
[Step 4: E-Portal Submission] -> LAR uploads files & pays government fee
|
[Step 5: Review & Deficiency] -> Resolve technical queries within 30 days
|
[Step 6: Registration Issued] -> Secure MOH Registration (5-Year Validity)
Step 1: Appointment of a Licensed Omani Agent
Appoint a local distributor or representative. The agent must hold a valid Medical Device Establishment License issued by the Omani MOH and be registered in the commercial register of the Ministry of Commerce, Industry and Investment Promotion (MOCIIP). Under Omani law, the establishment must have an MOH-approved storage warehouse.
Step 2: Manufacturer Pre-Qualification (GD-22)
Before registering individual devices, the foreign manufacturer's facility must be registered with the MOH Drug Safety Center.
- The LAR submits Guideline GD-22 documentation: the manufacturer’s corporate profile, list of manufacturing facilities, valid ISO 13485 certificate, and proof of reference-market approvals.
- Once approved, the manufacturer is assigned an official MOH Manufacturer Registry Number.
Step 3: Dossier Compilation (CSDT Format)
The dossier must be compiled using the Common Submission Dossier Template (CSDT). Key requirements include:
- Device Master File: Design data, raw materials, clinical evaluations, and risk analysis (ISO 14971).
- Certificates: ISO 13485, EC Certificate of Conformity (CE Mark), or FDA clearance letter.
- Free Sale Certificate (FSC): An official FSC from the country of origin, legalized by the Omani Embassy.
- Labeling and Packaging: High-resolution packaging artwork. Labels must be in English. For home-use devices, clear safety warnings and operating instructions must also be provided in Arabic.
Step 4: E-Portal Submission and Fee Settlement
The LAR logs into the MOH Drug Safety Center portal, links the application to the manufacturer's pre-qualification registry number, and uploads the CSDT folders. The government fee (OMR 100 or OMR 200) is paid electronically.
Step 5: Technical Review and Deficiency Resolution
MOH reviewers evaluate the submission. If discrepancies are found, they issue a Deficiency Report. The manufacturer and LAR typically have 30 days to upload responses. Failing to respond in time results in application rejection.
Step 6: Issuance of the Registration Certificate
Once approved, the MOH issues the Sanitary Registration Certificate. The product is added to the official register, allowing the LAR to secure import permits. The certificate is valid for 5 years.
Technical Audits and Local Administrative Barriers in Oman
While the 60-working-day timeline looks highly promising on paper, foreign manufacturers often encounter specific administrative bottlenecks that are unique to the Omani system:
1. The Consulate/Embassy Legalization Hurdle
Oman is not a party to simplified electronic document verification systems for all regulatory documents. The MOH Drug Safety Center requires the primary Free Sale Certificate (FSC) and the local Letter of Authorization (LoA) to be physically legalized at the Omani Embassy in the manufacturer's country of origin.
- The Problem: Legalization can take several weeks or even months depending on the jurisdiction. For instance, legalizing a document through the Omani consulate in Washington D.C. or London often requires prior authentication by local state departments or chambers of commerce, adding $500 to $1,500 USD per document in hidden fees.
- Strategy: Manufacturers must initiate embassy authentication at the very start of the project, parallel to the GD-22 manufacturer pre-qualification step, to avoid dossier bottlenecks.
2. High Deficiency Rates for Home-Use Products
Oman's technical committee pays close attention to any device intended for home use or direct consumer purchase (such as blood glucose monitors, wound dressings, or inhalation lines).
- The Trigger: If the labeling or instructions for use (IFU) do not clearly contain Arabic translations alongside the English text, the application is immediately flagged with a technical deficiency.
- Resolution: Ensure that the Arabic packaging translation is performed by a qualified medical translator and explicitly states the local representative's contact info.
Post-Market Surveillance and Technovigilance Requirements
Under the mature framework established by Circular 161/2025, securing a registration certificate is no longer the final step in compliance. Oman’s MOH has implemented strict post-market surveillance (PMS) and technovigilance rules to ensure patient safety:
- Adverse Event Reporting: The LAR must establish an online link with the MOH Drug Safety Center's vigilance department. Any adverse event occurring within Oman involving the device must be reported within 15 days of the agent becoming aware.
- Global Recall Integration: If a manufacturer issues a voluntary recall, safety warning, or field safety corrective action (FSCA) in a reference market like the EU or US, the LAR must notify the Omani MOH within 48 hours, detailing the serial numbers or lot codes imported into the Sultanate.
- Periodic Safety Update Reports (PSUR): For Class C and Class D devices, manufacturers must provide periodic safety reports to their local representative, who uploads them to the portal upon request or during the 5-year renewal window.
Strategic Local-Agent Selection and Channel-Lock-In Avoidance for Oman
For medtech companies entering Oman, the quantitative reality of local agent concentration (with Muscat Pharmacy holding 15.5% of the register) highlights the need for careful channel design:
- Evaluate the "Third-Party Hold" LAR Model: To maintain commercial flexibility, consider utilizing a neutral third-party regulatory consultant in Oman to act as your legal LAR. The consultant holds the MOH registrations, while you appoint different commercial distributors to handle logistics and sales. This prevents a single distributor from securing a regulatory monopoly over your product portfolio.
- Differentiate the "Medicated" Registry from General Devices: If your product is a standard device (e.g., surgical drapes, catheters, or orthopedic implants), ensure your regulatory team separates it from the "medicated devices" registry. Under the new Circular 161/2025, standard devices go through the new Class A-D e-portal pathway, which bypasses the drug-border checks, resulting in faster approval.
- Leverage Saudi SFDA Approvals: Because Oman's MOH works closely with the Saudi Food and Drug Authority (SFDA), having an active Saudi MDMA approval is a major advantage. Omani reviewers frequently accept Saudi evaluation reports, which can reduce timeline risks and clear technical queries.
Related Articles
To complete your GCC and Middle Eastern regulatory strategy, review our sibling guides:
- GCC Medical Device Registration: Qatar, Kuwait, Bahrain and Oman Guide — A regional framework overview detailing the e-portal links and shared GCC standards.
- Saudi SFDA Authorized Representative Concentration and Expiry-Risk Analysis — Analyzing the GCC's largest device market and local partner dynamics.
- UAE EDE Medical Device Supplier Concentration and Market-Entry Analysis — Navigating the Emirates' regulatory landscape and local representative structures.
Disclaimer: The data presented in this article is based on the official Oman Ministry of Health (MOH) Drug Safety Center registered medicated medical devices and approved establishment lists snapshot as of June 2026. Company and agent record counts are approximate due to spelling and name-case variations in the public records. This analysis is for educational and commercial planning purposes and does not constitute formal legal or regulatory advice for specific products.